Glioblastoma Pipeline Therapeutics Assessment, Treatment Drugs, Clinical Trials, and Companies 2024 (Updated)

DelveInsight's, "Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Glioblastoma Research. Learn more about our innovative pipeline today! @ Glioblastoma Pipeline Outlook- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Glioblastoma Pipeline Report
• In December 2024:- NovoCure GmbH- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant With Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58).
• In December 2024:- GT Medical Technologies Inc.- This study seeks to explore if GT, given its unique radiobiological and physical characteristics, may permit safe dose escalation and intensification and thereby provide a benefit to newly diagnosed GBM patients in terms of OS and LC when incorporated into the framework of the Stupp protocol. In this study, GT is utilized as an upfront boost at the time of maximum safe resection and dosimetrically integrated into what is otherwise standard of care therapy.
• DelveInsight's Glioblastoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioblastoma treatment.
• The leading Glioblastoma Companies such as Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies and others.
• Promising Glioblastoma Therapies such as Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others.

Stay informed about the cutting-edge advancements in Glioblastoma treatments. Download for updates and be a part of the revolution in care @ Glioblastoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioblastoma Emerging Drugs Profile

• Enzastaurin: Denovo BioPharma
DB102 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that has been studied in more than 3,000 patients across a range of solid and hematological tumor types. DB102 was originally developed by Eli Lilly and for which Denovo has acquired worldwide rights. DB102 received Orphan Drug Designation in DLBCL and glioblastoma multiforme (GBM) from the FDA and EMA and Fast Track Designation from the FDA. DB102 is the world's first oral small-molecule kinase inhibitor targeting PKC. A retrospective analysis found that it has significant curative effects in high-risk DLBCL patients who are DGM1 positive. The company has initiated a biomarker guided Phase III clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM).

• Asunercept: Apogenix
CAN008 (asunercept) is a CD95-Fc fusion protein that binds to the CD95 ligand and blocks the interaction between the ligand and the endogenous CD95 receptor. CAN008 has a unique dual mechanism of action, inhibiting both the invasive growth and migration of tumor cells, as well as T-cell apoptosis, which enhances immune recognition of the cancer. Earlier asunercept glioblastoma multiforme (GBM) clinical trial data showed favorable safety and tolerability, prolonged survival and improved quality-of-life. Asunercept has been granted US FDA Orphan Drug Designation and Orphan Medicinal Product Designation by the European Medicines Agency (EMA) for GBM. It has also been accepted into the EMA's PRIME (Priority Medicines) program, which provides support to medicines that could address unmet medical needs. In China, CAN008 has been classified as a Class 1 New Drug by the National Medical Products Administration. CANbridge holds the rights to develop and commercialize CAN008 for any indication in Greater China and is currently conducting a CAN008 Phase II trial in GBM in China.

• Berubicin: CNS Pharmaceuticals
Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Glioblastoma.

• Azeliragon: Cantex
Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of the receptor for advanced glycation end products (known as RAGE) with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment. Azeliragon was discovered by and originally under development for Alzheimer's disease by vTv Therapeutics from which Cantex licensed worldwide rights to azeliragon. Currently, the drug is in Phase II stage of its clinical trial for the treatment of glioblastoma, brain metastasis, pancreatic cancer, breast cancer.

• VXM01: VAXIMM
VXM01 is an oral T-cell immunotherapy that is designed to activate T-cells to attack the tumor vasculature and, in several tumor types, attack cancer cells directly. VXM01 carries the vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on the tumor vasculature and on certain cancer cells as the target gene. The active, T-cell-mediated destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue (inflammation). In preclinical studies, a murine analog VXM01 vaccine showed broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR2-specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Glioblastoma.

• MB-101: Mustang Bio
MB-101 is a CAR-T cell therapy developed by Mustang Bio that targets IL13Rα2, a protein expressed on the surface of certain glioma cells. The therapy involves the infusion of CAR-T cells that are engineered to recognize and bind to IL13Rα2, leading to the activation and proliferation of these cells. This results in the killing of glioma cells and the potential for long-term remission. MB-101 has shown promising results in clinical trials, including achieving complete responses in two patients with high-grade glioma, and has been well-tolerated with manageable side effects. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Glioblastoma.

Learn more about Metastatic Breast Cancer Drugs opportunities in our groundbreaking Glioblastoma Research and development projects @ Glioblastoma Unmet Needs- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioblastoma Companies
Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies, and others.

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Glioblastoma Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Glioblastoma treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Glioblastoma Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Glioblastoma Pipeline Report
• Coverage- Global
• Glioblastoma Companies- Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies and others.
• Glioblastoma Therapies- Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others.
• Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Glioblastoma Pipeline on our website @ Glioblastoma Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Glioblastoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Glioblastoma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Enzastaurin: Denovo BioPharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Asunercept: Apogenix
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MB-101: Mustang Bio
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Glioblastoma Key Companies
21. Glioblastoma Key Products
22. Glioblastoma- Unmet Needs
23. Glioblastoma- Market Drivers and Barriers
24. Glioblastoma- Future Perspectives and Conclusion
25. Glioblastoma Analyst Views
26. Glioblastoma Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2024

attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
external defibrillators market- https://www.delveinsight.com/report-store/external-defibrillators-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
ornithine transcarbamylase deficiency market- https://www.delveinsight.com/report-store/ornithine-transcarbamylase-deficiency-otc-deficiency-market
pediatric neuroblastoma market- https://www.delveinsight.com/report-store/neuroblastoma-market
schistosomiasis market- https://www.delveinsight.com/report-store/schistosomiasis-market
tcr therapy market- https://www.delveinsight.com/report-store/tcr-therapy-market
uk healthcare report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
vascular access devices market https://www.delveinsight.com/report-store/vascular-access-device-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
artificial disc market- https://www.delveinsight.com/report-store/artificial-disc-market
endoscopic ultrasound market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
overactive bladder syndrome market- https://www.delveinsight.com/report-store/overactive-bladder-market
respiratory syncytial virus market- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
shingles market - https://www.delveinsight.com/report-store/shingles-market
short bowel syndrome drug market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
cxcr inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
short bowel syndrome market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
catheter stabilization devices market- https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
celiac disease market- https://www.delveinsight.com/blog/celiac-disease-market-key-companies
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
pulmonary emphysema market- https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-treatment-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
nk cell therapy market- https://www.delveinsight.com/blog/nk-cell-therapy-in-cancer-treatment
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
chronic neuropathic pain market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
healthcare consulting solutions- https://www.delveinsight.com/consulting
skin neoplasm market- https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
meibomian gland dysfunction market- https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight
dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-epidemiology-forecast-insight
testicular neoplasm market- https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market
microscopy device market- https://www.delveinsight.com/sample-request/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.